Trials / Completed
CompletedNCT01981837
Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
A Phase 2, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Exploratory Clinical Activity of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the pharmacokinetics, pharmacodynamics and exploratory clinical activity of ALN-TTRSC (revusiran) in Patients with Transthyretin (TTR) Cardiac Amyloidosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALN-TTRSC (revusiran) for subcutaneous administration |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2014-10-01
- Completion
- 2015-01-01
- First posted
- 2013-11-13
- Last updated
- 2023-03-20
Locations
4 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT01981837. Inclusion in this directory is not an endorsement.